The clinical landscape of HIF2α inhibitors in oncology

A comprehensive review published in Nature Reviews Clinical Oncology examines the current clinical landscape of hypoxia-inducible factor 2α (HIF2α) inhibitors across multiple cancer types. Once considered undruggable, HIF2α has now been validated as a therapeutic target, with the review detailing the structural basis for its druggability and summarizing clinical results achieved to date. The authors discuss key challenges facing the field, including treatment-related toxicities and the need for predictive biomarkers to guide patient selection. The paper also explores emerging targeting modalities and combination strategies that may enhance efficacy, overcome resistance mechanisms, and broaden the indications for HIF2α inhibition beyond renal cell carcinoma.